In this study we assessed the safety, efficacy and costeffectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected for clinical trials. The number of enhancing lesions, the number of new enhancing lesions and the number of active scans were used to evaluate the sensitivity of the contrast-enhanced MRI to disease activity. The dose of Gd, and the effect of introducing a delay between the contrast injection and the scan were both appraised. Every 4 weeks for 3 months, and in two separate sessions, scans were obtained from 40 patients with relapsing-remitting or secondary progressive multiple sclerosis, 5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg) or triple dose (0.3 mmol/kg) Gd injection. There were 435 enhancing lesions (242 of which were new) on the early standard dose scans, 479 (263 new) on the delayed Keywords: multiple sclerosis; MRI, gadolinium-DTPA; triple dose; disease activity Abbreviations: BBB ϭ blood-brain barrier; CI ϭ confidence interval; CSE ϭ conventional spin-echo; EDSS ϭ Expanded Disability Status Scale; GT ϭ glutamyl transferase; Gd ϭ gadolinium-DTPA; TE ϭ echo time; TR ϭ repetition time © Oxford University Press 1998 standard dose, 772 (365 new) on the early triple dose and 827 (404 new) on the delayed triple dose. There were 109 scans revealing active disease on the early standard dose scans, 112 on the delayed standard dose, 119 on the early triple dose and 120 on the delayed triple dose. Statistical simulations indicated that the sample sizes needed for both cross-over and parallel-group trials with similar powers are lower if serial monthly triple dose MRI is used. No side-effects were reported and no significant changes in blood test parameters were found throughout the study. This study shows that the serial use of triple dose Gd is safe, and that it increases the sensitivity of serial monthly enhanced MRI in detecting multiple sclerosis activity significantly. Its use should enable preliminary trials of experimental therapies for multiple sclerosis to be conducted in small patient populations, over a short period of time.
Introduction
In multiple sclerosis, gadolinium-DTPA (diethylenetriaminepenta-acetic acid) (Gd) enhancing lesions seen on MRI scans represent areas with a damaged blood-brain barrier (BBB) and intense inflammation (McDonald et al., 1992; Katz et al., 1993) . Although the presence of Gd enhancement is correlated with clinical activity (Miller et al., 1988; Youl et al., 1991; Barkhof et al., 1992) and with short-term disease evolution (Smith et al., 1993) , it reveals phases of disease activity which occur 5-10 times more frequently than clinical relapses in patients with relapsing-remitting or secondary progressive multiple sclerosis (Miller et al., 1993) . In the same clinical subgroups, it is also significantly more sensitive to disease activity than unenhanced MRI, when using either conventional spin-echo (CSE) (Miller et al., 1993) or fast fluid-attenuated inversion recovery sequences (Filippi et al., 1998b) .
The high sensitivity of enhanced MRI in detecting multiple sclerosis activity has improved understanding of the disease evolution (Hartung et al., 1995; Rieckmann et al., 1995 Rieckmann et al., , 1997 Martino et al., 1996) , and may enable a treatment effect to be demonstrated in phase II trials, with relatively small patient cohorts followed up for short periods (McFarland et al., 1992; Nauta et al., 1994) . Recently, several strategies have been developed to further increase the sensitivity of enhanced MRI. Some of these approaches are designed to maximize the information which can be obtained by conventional scanning, by means such as more frequent MRI sampling (weekly instead of monthly) , a more complete evaluation of the CNS (spinal cord as well as brain) and an increased delay between Gd injection and scanning (20-30 min instead of the conventional 5-7 min) (Filippi et al., 1997b) . Other approaches are aimed at increasing the contrast of enhancing lesions using, for example, high doses of Gd (0.3 instead of 0.1 mmol/kg) (Filippi et al., 1995 (Filippi et al., , 1996a , the acquisition of thin slices (1 or 3 mm thick instead of the conventional 5 mm) (Filippi et al., 1996c) or magnetization-transfer weighting (Mehta et al., 1995) . At present, there is evidence van Waesberghe et al., 1997) that, of these separate approaches, the use of a triple dose Gd gives the maximum yield of active multiple sclerosis lesions, and it can be used in combination with other strategies to further improve sensitivity .
If these newer approaches are to be used in monitoring multiple sclerosis evolution, either natural or modified by treatment, they must be evaluated to ensure that the increased sensitivity is maintained in longitudinal studies. For triple dose scanning, it is necessary to know whether the increased cost of the contrast agent is offset by the reduced number of scans needed to demonstrate a treatment effect, and whether there are any side-effects. This study was performed (i) to evaluate and compare the total number of enhancing lesions, the number of new enhancing lesions and the number of active scans seen with serial monthly brain MRI after the injection of a standard dose and a triple dose of Gd in patients with multiple sclerosis; (ii) to evaluate whether a delay between the contrast injection and the scan increases the sensitivity of serial monthly standard dose and triple dose MRI; (iii) to calculate, by way of a computer simulation, the statistical power of phase II cross-over and parallel-group trials with fixed sample sizes, using the numbers of new enhancing lesions and active scans seen with different Gd doses as the outcome measures; and (iv) to evaluate the safety of serial administration of triple dose Gd.
Patients and methods Patients
Patients included had suffered from clinically definite multiple sclerosis (Poser et al., 1983) for at least 2 years, with a relapsing-remitting or a secondary progressive course (Lublin et al., 1996) and had an Expanded Disability Status Scale (EDSS) score (Kurtzke, 1983) between 0.0 and 6.0. None of them had taken immunosuppressive or immunomodulating treatments for at least 12 months prior to entry to the study. In addition, they had neither relapses nor steroid treatment during the preceding 3 months. MRI examinations were performed on all patients every 28 Ϯ 5 days on four separate occasions (i.e. the follow-up was of 3 months duration). Within 24 h of the MRI scan, each patient was assessed neurologically by the same rater at each centre (R.C., C.G., I.K. and V.M.) and disability was assessed using the EDSS. In cases of relapse which, according to the judgement of the local neurologist, required steroid treatment, the schedule always followed was intravenous methylprednisolone (1 g/day) for 3 days. The occurrence of a relapse and treatment of this type was recorded by the same neurologists who evaluated the EDSS scores. MRI was always scheduled either before the start of steroid treatment or 10 days after the end. No other immunosuppressive or immunomodulating treatment was allowed during the study. Local ethical committee approval at each centre and written informed consent from all the patients were obtained before study initiation.
MRI
Scanners operating at 1.5 T were used at all four centres, with three of the machines being from the same manufacturer. At each centre the same scanner was used for the duration of the study. On each scanning occasion, the MRI examination was split into two sessions, separated by an interval of 12-24 h. During the first session, the following scans were performed: (i) dual echo CSE [repetition time (TR) ϭ 2000-2400 ms, first echo echo time (TE) ϭ 30-50 ms, second echo TE ϭ 80-100 ms, number of acquisitions ϭ 1]; (ii) pre-contrast T 1 -weighted CSE (TR ϭ 560-768 ms, TE ϭ 14-15 ms, number of acquisitions ϭ 2); two post-contrast T 1 -weighted scans, with the same acquisition parameters as before the Gd injection, 5 min (early post-contrast scans) and 20 min (delayed post-contrast scans) after the injection of Gd. During the second session, the following were performed with the same parameters as above: (i) pre-contrast T 1 -weighted scan; (ii) two post-contrast T 1 -weighted scans 5 min and 20 min after the Gd injection. The dose of Gd was randomized so that in the first session the patient received either a standard dose (0.1 mmol/kg) or triple dose (0.3 mmol/kg) of Gd, with the other dose given during the second session. Thus, on each monthly occasion, each patient had four post-contrast T 1 -weighted scans, i.e. early and delayed standard dose scans and early and delayed triple dose scans. The randomization was performed for each patient on each scanning occasion with no attempt to equalize the numbers having the standard dose or triple dose first, or to make sure that each patient had equal numbers of standard dose and triple dose scans first.
For all the scans, 24 contiguous interleaved axial slices were acquired with 5 mm slice thickness, ϫ 256 matrix size and 220-250 mm giving an in-plane spatial resolution of about 1 ϫ 1 mm at each centre. The same acquisition protocol was used for the duration of the study. For follow-up scans, the scan planes were carefully repositioned according to published guidelines (Miller et al., 1991) .
Safety assessment
At the end of each scanning session, the patients, who were unaware of the Gd dose used, were asked about any discomfort or side-effects related to Gd administration. This was repeated by telephone 2 days after the completion of each monthly visit. The questions were posed by the same observers (R.C., C.G., I.K. and V.M.) at each centre for the entire duration of the study. Every 28 Ϯ 5 days, prior to the MRI examination blood was collected from each patient in a routine manner for performance of the following types of chemical and haematological analysis: red and white blood cell counts, platelet count, haemoglobin level, haematocrit, mean corpuscular volume, blood urea and creatinine, and levels of aminotransferase aspartate, aminotransferase alanine, γ-glutamyl transferase (γ-GT), alkaline phosphatase, total bilirubin and iron. These tests were performed by the central clinical chemistry laboratories operating in each centre according to their standard procedures. Abnormal results were considered to be those falling outside the normal ranges of each laboratory.
Image review
The enhanced T 1 -weighted scans were assessed to determine the total number of enhancing lesions and the number of new enhancing lesions, in a way described in previously published guidelines . The assessment process has three stages.
Stage 1
Each of the four sets of post-contrast T 1 -weighted images from each patient was viewed in a consensual fashion by two of us (M.F. and M.R.) with the films presented in random order. The observers were unaware of the Gd dose, the scanning delay, the patient to whom the scans belonged and the time point of the acquisition.
Stage 2
Next, the four sets of images obtained at each time point from each patient were compared in order to evaluate whether lesions seen on some, but not all, the scans could be seen retrospectively on the others. The observers were still unaware of the Gd dose used, the scanning delay and the patients' clinical characteristics. Thus, after this stage, each lesion had been reassessed.
Stage 3
For each patient, and for the two Gd doses and delay times, the four monthly scans were evaluated side-by-side to count the new enhancing lesions.
Throughout the entire image evaluation process, the corresponding dual-echo and pre-contrast T 1 -weighted scans were used to confirm possible areas of enhancement.
At the end of the image review process, enhancing lesions were marked on the hard copies. The reproducibility measures for enhancing lesion counts are similar for standard dose and triple dose scans, and both are very high (Filippi et al., 1997a) . For each patient, the same two observers also identified and marked lesions visible on the entry and exit T 2 -weighted scans. A single technician, unaware of the Gd dose used, the scanning delay, the patient to whom the scans belonged and the time point of the acquisition, measured the volumes of enhancing lesions (on all the scans) and T 2 lesions (only just the entry and exit scans) using a semiautomated local thresholding technique, with a high intraand inter-rater reproducibility .
Statistical analysis
The effect of Gd dose and scanning delay on the numbers of total and new enhancing lesions was studied using a Poisson regression model with patients as blocks. The significance of the effect was tested using the likelihood ratio test. An ANOVA (analysis of variance) model was used to assess the effect of Gd dose and scanning delay on the enhancing lesion volume. The differences between entry and exit lesion volumes seen on the T 2 -weighted scans were also assessed. The effect of Gd dose and scanning delay on the proportion of scans with at least one enhancing lesion, and the proportion of scans with at least one new enhancing lesion were studied using a logistic regression, with patients as blocks. The significance of the effect was tested using the likelihood ratio test.
Computer simulations were performed according to the method used by Nauta et al. (1994) , Truyen et al. (1997) and Tubridy et al. (1998) to estimate the statistical power for clinical trials with two-period cross-over and parallelgroup designs. The number of new enhancing lesions and the number of active scans seen on the early standard dose and triple dose images were used as the outcome variables. For the simulations, active scans were considered to be those with at least one new enhancing lesion. Also, the number of new enhancing lesions, rather than the total number of enhancing lesions, was chosen as the most appropriate measure, since an effective treatment is more likely to stop new lesion development than to shorten the duration of enhancement. This approach has been used previously by other investigators (McFarland et al., 1992; Nauta et al., 1994; Truyen et al., 1997; Tubridy et al., 1998) . The 40 patients studied for 3 months were considered representative of the 'untreated' multiple sclerosis population. The first stage of the approach consisted of simulating the treatment effect. For each lesion and for each scan revealing active lesions in the 'untreated' group, a Bernoulli trial was performed with a probability of success set to the desired treatment effect; a success resulted in the disappearance of the lesion or of the entire activity on individual scans. In this way, a 'treated' group (i.e. 40 patients with a 3 month follow-up) was created for each treatment effect. This process was conducted independently for standard dose and triple dose scans. This approach is based on the assumptions that the experimental treatment is effective immediately, and that the effect is identical for all types of lesion, at all times and in every patient. The second stage of the simulation consisted of generating 1000 trials for each study design: the trials were simulated by drawing random sets of different sizes from the data (sampling with replacement). The baseline scan was supposed to be taken once for each patient before the initiation of the study period. The power was calculated as the proportion of trials which yielded a significant result for two groups of 10-40 patients followed for 6 months (i.e. 3 months for each period) for the two-period cross-over design and for two groups of 20-50 patients followed for 3 months for the parallel-group design. The tests used in simulations were the Wilcoxon signed rank test for the crossover design and the Wilcoxon rank sum test for the parallelgroup design, as used in previous studies (Nauta et al., 1994; Truyen et al., 1997; Tubridy et al., 1998) . The results of the simulations obtained for the two-period cross-over design are also applicable to single cross-over trials (McFarland et al., 1992) .
Results

Clinical data
Forty patients (26 women and 14 men) entered the study and completed the follow-up. Thirty-seven had a relapsingremitting and three a secondary progressive disease course. Their mean age was 34.7 years (range, 20-65 years), mean disease duration was 7.0 years (range, 2-21 years) and median EDSS at entry was 2.0 (range, 0.0-6.0). Thirteen relapses were recorded during the follow-up period in 11 patients; 11 relapses were treated.
Safety assessment
There were no reports of discomfort or side-effects over the entire duration of the study, either immediately after each Gd injection or when the patients were interviewed 2 days later. In Table 1 , the mean values and standard deviations for the blood test results are shown. No permanent and significant changes in the blood test parameters were found during the follow-up: only six increases in total bilirubinaemia (in four patients), five reductions in haematocrit (four patients), two increases of mean corpuscular volume (in two patients), two increases in serum iron level (in two patients) and one increase in serum γ-GT level were observed. All these changes were within one standard deviation of the normal range for the different laboratories.
MRI
The median T 2 -lesion loads were 10.6 ml (range, 0.7-59.6 ml) at entry and 11.2 ml (range, 0.7-57.6 ml) at exit (no significant difference). The median percentage change of T 2 -lesion load was ϩ1% (range, Ϫ29 to 156%). No enhancing lesions were observed on the pre-contrast T 1 -weighted scans performed at the beginning of each second scanning session.
A total of 640 post-contrast scans were obtained and analysed (160 for each of the four MRI techniques). Tables  2 and 3 show the total number of enhancing lesions and the number of new enhancing lesions as well as the mean and median numbers (with standard deviations and ranges) per month seen using early and delayed standard dose and triple dose scans. There was no significant interaction between dose and scanning delay, both on the total number of enhancing lesions (P ϭ 0.74) and on new enhancing lesions (P ϭ 0.83). Therefore, these effects were excluded from the final Poisson regression model, which showed that the use of the triple dose and delayed scanning have independent effects on the detection of both the whole population of enhancing lesions and new enhancing lesions. For the reference situation (i.e. standard dose and early scanning), the mean estimated total number of enhancing lesions was 2.73 [95% confidence interval (CI) ϭ 2.54-2.96] per patient per month and the estimated number of new enhancing lesions (standard dose and early scanning) was 2.01 (95% CI ϭ 1.80-2.22) per patient per month. Compared with the early standard dose scans, delayed standard dose scans showed a 10% (95% CI ϭ Ϫ2 to 23%) increase (P ϭ 0.09) in the total number of enhancing lesions and 8% (95% CI ϭ 0-17%) more (P ϭ 0.04) new enhancing lesions; early triple dose scans showed a 75% (95% CI ϭ 61-90%) increase (P Ͻ 0.001) in the total number of enhancing lesions and 52% (95% CI ϭ 36-70%) more (P Ͻ 0.001) new enhancing lesions. The numbers of scans with at least one enhancing lesion were 109 (68%) for early standard dose, 112 (70%) for delayed standard dose, 119 (74%) for the early triple dose and 120 (75%) for the delayed triple dose. The proportion of scans with at least one enhancing lesion was significantly lower for standard dose compared with triple dose scans (P ϭ 0.01), while there was no significant effect of scanning delay (P ϭ 0.57). The numbers of scans with at least one new enhancing lesion were 70 (58%) for early and delayed standard dose and 77 (64%) for the early and delayed triple dose (P ϭ 0.04).
In Table 4 , the means, medians, standard deviations and ranges of enhancing lesion volumes seen using the four contrast administration strategies are reported. Compared with early standard dose scans, the use of the triple dose (P Ͻ 0.001) and delayed scanning (P ϭ 0.005) increased the measured enhancing lesion volumes significantly. However, the interaction of these two factors was not significant (P ϭ 0.99).
Tables 5-8 show the results of the simulated cross-over and parallel-group trials. In Tables 5 and 6, the outcome measure was the number of new enhancing lesions, while for Tables 7 and 8 the outcome measure was the proportion of active scans. For these trial design and outcome measures, the use of a triple dose of contrast agent allows fewer scans to be performed to detect the same treatment effect with comparable statistical power. Below are a few illustrative examples of the increased power.
(i) For a cross-over design with a power Ͼ95% using the number of new enhancing lesions as the outcome measure, 280 standard dose (40 baseline scans and 120 for each trial period) or 140 triple dose (20 baseline scans and 60 for each trial period) MRI scans are needed to detect a treatment effect of 50% (Table 5) .
(ii) For a parallel-group design with a power of~80% using the number of new enhancing lesion as the outcome measure, 320 (80 baseline scans and 240 scans for the 3 month follow-up) standard dose or 240 (60 baseline scans and 180 scans for the 3 month follow-up) triple dose MRI scans are needed to detect a treatment effect of 70% (Table 6) .
(iii) For a cross-over design with a power of 94% using the proportion of active scans as the outcome measure, 560 standard dose (80 baseline scans and 240 for each trial period) or 420 (60 baseline scans and 180 for each trial period) triple dose MRI scans are needed to detect a treatment effect of 20% (Table 7) .
(iv) For a parallel-group design with a power of 82% using the proportion of active scans as the outcome measure, 400 (100 baseline scans and 300 scans for the 3 month followup) standard dose or 240 (60 baseline scans and 180 scans for the 3 month follow-up) triple dose MRI scans are needed to detect a treatment effect of 50% (Table 8) .
Discussion
This study suggests that the serial use of a triple dose Gd to monitor, for a short-term period, disease evolution in multiple sclerosis is safe and, as a consequence of the significantly increased sensitivity in detecting active lesions, MRI- monitored phase II trials could be conducted using considerably fewer scans than when using the standard dose. There are implications both for understanding the nature of enhancing lesions in multiple sclerosis, and for monitoring any treatment effect.
The nature of enhancing lesions in multiple sclerosis
This study shows that, in agreement with several previous cross-sectional studies (Filippi et al., 1995 (Filippi et al., , 1996a (Filippi et al., , b, c, 1997b Mehta et al., 1995; Lai et al., 1996; Thorpe et al., 1996; Silver et al., 1997; van Waesberghe et al., 1997) , a large percentage of active lesions go undetected if conventional enhanced MRI is used. Over the 3 month follow-up period, the triple dose showed 75% more lesions than the standard dose, and of these~50% were new. There are two possible explanations for the increased sensitivity of triple dose scanning. The first is that the time course of BBB leakage for some lesions is such that they might be detectable with standard dose scanning for only a part of the inflammatory episode. The second is that the BBB permeability is too low for enhancement ever to be seen with standard dose contrast administration. The pathological substrate of enhancing multiple sclerosis lesions is a damaged BBB associated with inflammation (McDonald et al., 1992; Katz et al., 1993) . When this occurs, the conspicuity of regions of enhancement is dependent on the local concentration of Gd, which is in turn dependent on the vascular concentration of Gd, the BBB permeability and the size of the leakage space (Tofts and Kermode, 1991) . It is well known that, soon after the appearance of a new multiple sclerosis lesion, which almost invariably enhances (McDonald et al., 1992) , reparative mechanisms are activated (Prineas et al., 1993) . Thus, it is likely that lesions at the beginning or at the end of the inflammatory episode have a less permeable BBB, and that this subtle abnormality can be seen by increasing the vascular concentration of Gd or by allowing more time for Gd molecules to diffuse into the leakage space. It is possible that weekly standard dose MRI would reveal some of these lesions. Lai et al. (1996) demonstrated that, although the majority of the multiple sclerosis lesions enhance for between 4 and 8 weeks, a few enhance only for shorter periods. The ability to detect such lesions during the course of a clinical trial must be weighed against the added inconvenience to the patients and the extra cost of weekly scanning.
Since from previous data it seems unlikely that a substantial fraction of the additional lesions seen with triple dose and delayed scanning are transiently enhancing, such lesions, regardless of their age, might have either a less severe disruption of the BBB, or a larger leakage space. In the present study, the post-contrast scans were obtained only 5 and 20 min after the Gd injection. With a delay this short between the injection and the scan, the leakage space has little influence on the local concentration of Gd (Tofts and Kermode, 1991) , thus suggesting that the additional lesions we have seen using the triple dose were those with a less damaged BBB. Recent work using magnetization-transfer imaging (Filippi et al., 1998a) suggests that in standard dose lesions, more severe tissue disorganization has occurred and that the degree of BBB and of brain tissue damage run in parallel, probably as the result of a more aggressive pathological process. This suggests that triple dose lesions are less important for disease evolution, which may be of concern for phase III trials, where the detection of functionally relevant lesions is important. However, it has fewer implications in the context of phase II trials, which should use very sensitive techniques to obtain information about the potential effectiveness of a new treatment in as short a time as possible.
Previous studies indicated that there are two types of enhancing lesion in multiple sclerosis: one with uniform enhancement, reflecting new lesion formation, and the other with ring-like enhancement, showing re-activation at the edges of pre-existing lesions (McDonald et al., 1992) . Using magnetization-transfer imaging, it was shown that the pathological nature of these two types of lesion is different, with ring-enhancing lesions exhibiting more severe tissue disorganization (Hiehle et al., 1995; Campi et al., 1996) . Our data suggest that the range of types of enhancement is even wider, which is in keeping with the heterogeneity in the nonenhancing multiple sclerosis lesion population (McDonald et al., 1992; Filippi and Miller, 1996a) . Further investigation of these issues may lead to a better understanding of multiple sclerosis evolution and the mode of action of treatment. Issues which deserve investigation include: the contribution which the additional active lesions make to the evolution of multiple sclerosis; their effect on the correlation with other markers of disease activity; and whether the action of drugs known to reduce BBB disturbance, such as high dose steroids (Barkhof et al., 1991; Miller et al., 1992) and β-interferon 1a (Jacobs et al., 1996) and 1b (Stone et al., 1995; Calabresi et al., 1997) , is different across the range of lesion types.
Implications for phase II clinical trials
The high sensitivity to disease activity of enhanced MRI enables phase II multiple sclerosis clinical trials to be conducted with significantly smaller patient cohorts and shorter follow-up periods than when clinically derived endpoints are used (McFarland et al., 1992; Nauta et al., 1994) , thus, saving both and time and expense. The recent improvements in sensitivity (Filippi et al., 1995 (Filippi et al., , 1996a (Filippi et al., , b, c, 1997b Mehta et al., 1995; Lai et al., 1996; Thorpe et al., 1996; Silver et al., 1997; van Waesberghe et al., 1997) should enable phase II trials to be performed with even fewer patients and shorter follow-up periods. Two cross-sectional studies van Waesberghe et al., 1997) suggest that the use of the triple dose Gd gives the biggest increase in sensitivity. However, before any of these newer strategies are used in clinical trials, it is necessary to demonstrate their sensitivity, cost-efficiency and safety when used serially.
Standard dose Gd has been administered serially for several years to large numbers of multiple sclerosis patients for monitoring disease evolution, with few and only mild sideeffects. This anecdotal evidence was confirmed by a formal study which evaluated the safety of serial monthly administration of Gd in 56 patients over a 4 year period (Tresley et al., 1997) . Several hundred patients with neurological diseases, including multiple sclerosis, have received a single administration of triple dose Gd with no severe or permanent side-effects (Haustein et al., 1993; Filippi et al., 1995 Filippi et al., , 1996a Silver et al., 1997; van Waesberghe et al., 1997) . The experience with the standard dose is reassuring, since the cumulative dose of Gd over such a long period is much higher than when a triple dose is administered monthly for the usual duration of a phase II trial (i.e. 4-6 months).
The results of the simulations suggest that the use of triple dose Gd in phase II clinical trials is cost-efficient. However, because of the limitations of using simulations (see the Patients and methods section), this should be treated with caution. The numbers presented in the Tables 5-8 should not be taken literally, but they should be used for the purposes of comparing the different Gd doses. Nevertheless, our data suggest that for both cross-over and parallel-group trials, in many circumstances the number of scans may be reduced by about one-third when a triple dose is used. Without putting a value on the lessened inconvenience to the patients, but estimating the additional cost of Gd to be 200-300 US$ per scan, and the cost of a scan to be 800-1000 US$, it is easy to see that a one-third reduction in the number of scans results in a significant cost saving. However, for delayed scanning, whether the standard dose or triple dose is used, the gain in sensitivity and the consequent reduction in the number of scans might not balance the cost of the longer study duration. Of course, if the time between Gd injection and the T 1 -weighted scan acquisition can be used to acquire other useful MRI data, then this argument does not hold.
The use of small sample sizes or short follow-up periods in multiple sclerosis treatment trials may, however, be of some concern. It is possible that a small sample is not fully representative of a wider multiple sclerosis population and that short follow-up periods do not allow slowly-developing treatment effects to be observed. These factors may lead to unexpected findings when larger phase III trials are performed. Although these potential problems also apply, to some extent, to the current use of standard dose Gd in MRI, they point to a need for trial designs specific to the treatment being tested. For example, if a drug is likely to take effect a few months after treatment begins, it is not advisable to monitor it with serial monthly triple dose Gd in MRI starting soon after drug initiation.
In conclusion, this study shows that the use of triple dose Gd for monitoring the activity of multiple sclerosis is safe, cost-efficient and very sensitive to short-term changes. It also suggests that this approach may lead to a better understanding of the formation and evolution of multiple sclerosis lesions.
